抗糖尿病新药格鲁辛胰岛素  

A new antidiabetic agent-insulin glulisine

作　　者：姜文清[1] 吴学军[1] 邹定[1] 马捷[1] 李金娥[1] 

机构地区：[1]卫生部北京医院药学部,北京100730

出　　处：《中国新药杂志》2006年第6期478-480,共3页Chinese Journal of New Drugs

摘　　要：综述了格鲁辛胰岛素的作用机制、药动学及临床评价。格鲁辛胰岛素是一种最新通过美国FDA批准的快速胰岛素类似物,用于控制1型和2型糖尿病。与常规胰岛素相比,它起效快,维持作用时间短,与长效胰岛素合用或用于胰岛素泵,可维持正常的血糖控制。Insulin glulisine （Apidra） is a new and recently approved rapid-acting insulin analogue. It is used to treat patients with type 1 or type 2 diabetes for the control of blood sugar level. Insulin glulisine onsets faster but lasts effects shorter than regular insulins. Combination of glulisine with other longer-acting insulin or glulisine alone as insulin pump therapy may more properly maintain normal blood sugar level. This paper reviewed the pharmacology, pharmacokinetics and clinical therapy of insulin glulisine.

关 键 词：格鲁辛胰岛素 快速胰岛素类似物 糖尿病 

分 类 号：R977.15[医药卫生—药品]